Clinical Trial

How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver

Study acronym: AGL14
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and type 2 diabetes. Type 1 diabetes (T1D) is also associated with a marked increase in the release of fat from adipose tissues and MASLD is increased in T1D and significantly increases the risk of heart, kidney and eye diseases.
Trial Details
NCT Number NCT07133854
Lead Sponsor Université de Sherbrooke
Collaborators: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Conditions Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH), Type 1 Diabetes Mellitus
Enrollment 32 participants
Start Date 2026-09
Primary Completion 2027-09 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-21